Medscape

P-tau217 Blood Test Can Identify Preclinical AD in Asymptomatic Patients

Plasma measures of phosphorylated tau217 (p-tau217) can accurately identify individuals in the preclinical stage of Alzheimer’s disease (AD), a new meta-analysis showed. The results are important ...
Seeking Alpha

Acumen Pharmaceuticals Showcases pTau217 Trial Screening Progress in Phase 2 ALTITUDE-AD Trial and Preclinical Research Methods at AD/PD 2025 and AAN Annual Meeting

NEWTON, Mass., April 02, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (ABOS) (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic ...
Fierce Biotech

Quanterix's blood test for Alzheimer's disease uncovers potentially treatable population in decades-long study

Alzheimer’s disease blood test developer Quanterix put forward new clinical data from its Simoa assay, which it described as ...
Business Wire

Vivodyne to Replace Animal Testing With $40 Million Funding to Reverse 95% Clinical Trial Failure Rate

95% of clinical trials fail because animal testing is no substitute for human biology - Vivodyne’s robotics platform grows thousands of human tissues daily, directly tackling the biological gap behind ...
New Atlas

Pancreatic cancer vaccine eradicates trace of disease in early trials

We could be on the verge of a major cancer treatment breakthrough, with a new vaccine shown to completely obliterate pancreatic cancer cells in preclinical trials. This paves the way for it to move ...